In this paper the authors study the association of thrombophilia gene polymorphism in patients with superficial venous thrombosis (SVT), and compare and analyse the same thrombophilia gene polymorphic variants in patients with deep venous thrombosis (DVT). The association of gene mutations leading to thrombophilia and the risk for developing DVT is well established. 1 Conversely, SVT and the associated thrombophilia mutations are less well defined. 2, 3 The clinical importance of SVT leading to venous thromboembolism was recently studied. The potential danger of SVT is that it is a marker for potential extension of thrombus into the deep venous system, with consequences leading to venous thromboembolism in as many as 44% of patients. 3 In this study, the authors find that the frequency of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism (+/+ carried on both alleles) was significantly higher in patients with varicose veins and SVT (24%) compared with DVT (4%) with an odds ratio of 7.95 (CI 0.90; 69.8, P , 0.05). In addition, the study found that patients with SVT had fewer factor V Leiden and prothrombin 20210 gene mutations. In this study all patients with SVT had varicose veins. It is important to note that there were primary trunk varices recorded in six patients with DVT, all originating from the greater saphenous vein, with the following MTHFR 677/1298 polymorphisms: three patients with 2/2 , +/2 ; and three patients with +/2 , 2/2, respectively. Of interest, in the SVT patients studied 93% had the thrombosis limited to below the saphenofemoral junction, and only 7% had their thrombus extending proximal to the saphenofemoral junction and into the deep system. In one patient the SVT was both in the greater saphenous vein and small saphenous vein, and in four patients the SVT was localized in the small saphenous vein. Interestingly, 62% of patients with SVT underwent surgery (the indications/details are not described in the manuscript). Medical treatment was provided for 38% of patients with SVT. Unfortunately, the paper did not discuss the indications for performing surgery in the group of patients with SVT. It is unclear what factors should necessitate surgical interven-tion, but one can surmise that propagation of thrombus in proximity to the deep venous system, inability to comply with anticoagulation and persistent pain may have contributed. It is unclear how to best treat SVT due to lack of randomized controlled trials, but current practices include anticoagulation, surgery, compression and anti-inflammatory drugs. 4 Because this study specifically evaluated patients with SVT all of which had varicose veins and polymorphic gene variants for thrombophilias, an important question is determining the prevalence of patients with varicose veins that have thrombophilias? In a recent study the purpose was to investigate the prevalence of thrombophilias and varicose veins. In varicose vein versus control patients the prevalence of one and multiple thrombophilias were significantly greater in patients with varicose vein (52% versus 26% and 15% versus 11%, respectively). 5 However, one should note that patients with SVT that do not have visible varicose veins are at increased risk for extending thrombus into the deep veins. Specifically, in patients with SVT and normal veins, thrombophilias were present in 62.5% of patients that had extension of thrombus into the deep veins, whereas in patients with varicose vein and SVT, the presence of thrombophilia and extension to deep veins was 36.3%. 6 Although this paper suggests that there may be a link between MTHFR in the pathogenesis of varicose vein disease and its thrombotic complications, the study's objective was to compare the genetic background of SVT in patients with varicose vein with patients with DVT. It is unknown what the role of MTHFR is in the pathogenesis of varicose veins. However, as this study discusses that the 'incidence of varicose vein disease parallels the worldwide distribution of the MTHFR C677T-polymorphism, both being low in Asians or blacks, intermediate in central Europeans and high in southern Italians and Hispanics'. 7 This is of significant value since it provides clues that varicose veins are genetically linked and affecting different population races differently based on their genetic polymorphic profile that has congenital and environmental influences. From this study an important question to ask would be: how does MTHFR influence the pathogenesis of varicose veins and how is it linked to SVT? Because MTHFR is an enzyme that is important in homocysteine metabolism, alterations in the enzyme function (as seen in gene polymorphic variants) could lead to elevated levels of homocysteine, free radical formation and endothelial damage. This could potentially lead to oxidative stress and dysfunctional endothelium. A study determined that protein S, vWf, VEGF and IL-12 were elevated in patients with primary varicose veins, but compared with controls, the levels of protein C, fibrinogen, homocysteine and PGI 2 were not significantly different. Further studies are needed to understand how MTHFR may affect the role of molecules such as NO, oxidative stress and cytokines that are expressed during stress. 8 Although this study demonstrated that MTHFR C677T polymorphism was significantly higher in patients with varicose veins with SVT compared with DVT patients, several issues arise: (1) What is the significance of a patient with MTHFR C677T polymorphism and the risk for developing SVT?;
(2) What is the significance of a patient with MTHFR C677T polymorphism with an SVT in the varicose veins and the risk of propagating into the deep venous system?; (3) What is the best treatment in a patient with MTHFR C677T polymorphism with or without SVT and varicose veins?; (4) Should patients with varicose veins have genetic testing for thrombophilias?; and (5) What are the socioeconomic impacts on society and health care in assessing thrombophilias in patients with varicose veins? This study was not designed to answer these questions; however, these are important questions that are relevant to providers treating patients with varicose veins given that there are well over 25 million people in the USA with varicose veins. 9 Future studies will be required to evaluate gene polymorphism in patients with chronic venous disease and varicose veins, and provide guidelines in further testing and management of a significant disorder that affects many individuals.
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